What question did this study set out to answer?

To identify a subset of HER2+ breast cancer patients who significantly benefit from trastuzumab using computational methods.

April 3, 2026Open Access

Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation

Key Points

To identify a subset of HER2+ breast cancer patients who significantly benefit from trastuzumab using computational methods.
Utilized computational techniques to derive spatial immune signatures.
Analyzed data from the NSABP B41 clinical trial.
Identified biomarkers associated with treatment response.
A specific subset of HER2+ patients showed enhanced response to trastuzumab.
Findings indicate the feasibility of using immune architectures to guide therapy selection.
Supports the role of computational approaches in improving treatment outcomes.

Abstract

DeSTIL identifies a subset of HER2+ patients who derive greater benefit from trastuzumab. These findings support the potential of computationally derived immune architecture to inform selection of standard HER2-targeted therapies.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Bharadwaj et al. (Tue,) studied this question.

synapsesocial.com/papers/69cf5eee5a333a821460db2e https://doi.org/https://doi.org/10.1158/1078-0432.ccr-25-4185

Bookmark

View Full Paper